Thiazolidinedione use and the risk of fractures
| Autor: | Tjark Reblin |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Canada medicine.medical_specialty Bone density medicine.drug_class Risk Assessment Rosiglitazone Fractures Bone Sex Factors Bone Density Risk Factors Internal medicine medicine Humans Hypoglycemic Agents Letters Sex Distribution Thiazolidinedione Clinical Trials as Topic Pioglitazone business.industry Incidence Research Incidence (epidemiology) Follow up studies General Medicine Middle Aged Surgery Treatment Outcome Increased risk Diabetes Mellitus Type 2 Female Thiazolidinediones business Risk assessment Follow-Up Studies |
| Zdroj: | Canadian Medical Association Journal. 180:841-841 |
| ISSN: | 1488-2329 0820-3946 |
| DOI: | 10.1503/cmaj.1090005 |
| Popis: | The recent commentary by Lorraine Lipscombe[1][1] gave the impression that the 10-study meta-analysis by Loke and colleagues yields a new finding that there might be an association between thiazolidinediones and an increased risk of fractures in women.[2][2] In fact, this finding largely replicates |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|